Email this article TOXICITY AND HAZARD OF ZOLMITRIPTAN (EXPERIMENTAL STUDY)
- Authors: Bidevkina M.V.1, Golubeva M.I.2, Bobrineva I.A.2, Limantsev A.V.1, Potapova T.N.1, Razumnaya I.N.2, Savchenko A.Y.3, Ramenskaya G.V.4
-
Affiliations:
- Scientific Research Disinfectology Institute of Rospotrebnadzor
- Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»
- Scientific Center for Biomedical Technology of the Federal Medical Biological Agency of the Russian Federation
- I.M. Sechenov First Moscow State Medical University
- Issue: No 5 (2020)
- Pages: 57-60
- Section: New information on toxicity and hazard of chemical and biological substances
- Published: 05.11.2020
- URL: https://rjpbr.com/0869-7922/article/view/641271
- DOI: https://doi.org/10.36946/0869-7922-2020-5-57-60
- ID: 641271
Cite item
Full Text
Abstract
Zolmitriptan is a widely used antimigraine drug, belongs to the group of second-generation tryptans, has a pronounced central mechanism of action and high selectivity to serotonin receptors of 5HT1D- and 5HT1B-types. Zolmitriptan belongs to hazard class 3 according to GOST 12.1.007-76: DL50 are 660 (495 - 881) mg/kg for male mice and 1045 (749 - 1292) mg/kg for female mice when administered into the stomach. When injected into the abdominal cavity, DL50 is 172 (131 - 225) mg/kg for male mice. The drug has a weak irritating effect on the mucous membranes of the eyes, does not irritate the skin, there are no signs of skin-resorptive action, and has a low ability to accumulate. The threshold of acute inhalation action is set at 0,9 mg/m3 for the effect on the functional state of the nervous system and liver. For the zolmitriptan aerosol, it is recommended to approve the tentative safe exposure level in the air of the working area at 0,01 mg/m3 and the tentative safe exposure level in the atmospheric air of urban and rural settlements at 0,0001 mg/m3.
Keywords
About the authors
M. V. Bidevkina
Scientific Research Disinfectology Institute of Rospotrebnadzor
Author for correspondence.
Email: bidevkinamv@niid.ru
Bidevkina Marina Vasil’evna
117246, Moscow
Russian FederationM. I. Golubeva
Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»
Email: golubevamargo@mail.ru
Golubeva Margarita Ivanovna
142450, Staraya Kupavna, Moscow region
Russian FederationI. A. Bobrineva
Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»
Email: ural955@mail.ru
Bobrineva Irina Alekseevna
142450, Staraya Kupavna, Moscow region
Russian FederationA. V. Limantsev
Scientific Research Disinfectology Institute of Rospotrebnadzor
Email: av.lim@yandex.ru
Limantsev Anatoliy Vladimirovich
117246, Moscow
Russian FederationT. N. Potapova
Scientific Research Disinfectology Institute of Rospotrebnadzor
Email: potapovatn@niid.ru
Potapova Tat›yana Nikolaevna
117246, Moscow
Russian FederationI. N. Razumnaya
Joint-Stock Company «All-Union Scientific Center for the Safety of Biologically Active Compounds»
Email: irina.r.3@mail.ru
Razumnaya Irina Nikolaevna
142450, Staraya Kupavna, Moscow region
Russian FederationA. Yu. Savchenko
Scientific Center for Biomedical Technology of the Federal Medical Biological Agency of the Russian Federation
Email: alursav@mail.ru
Savchenko Аlla Yur’evna
143442, Svetlye Gory Village, Krasnogorsk District, Moscow region
Russian FederationG. V. Ramenskaya
I.M. Sechenov First Moscow State Medical University
Email: ramenskaia@mail.ru
Ramenskaya Galina Vladislavovna
119991, Moscow
Russian FederationReferences
- Kalashnikova L.A. Zomig – a new selective serotonin receptor agonist in the treatment of migraine attacks. Neurological journal; 1999; 4 (4): 37-40 (in Russian).
- Evolution of views on the causes of migraines. International neurological journal; 2009; 5(27). Available at: http://www.mif-ua.com/archive/article_print/11306 (accessed 02 August, 2019) (in Russian).
Supplementary files
